Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Tofacitinib is a relatively novel therapy for immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a small-molecule drug that exerts its effects by inhibiting Janus kinases. Recently, concerns have been raised about...

Descripción completa

Detalles Bibliográficos
Autores principales: Bezzio, Cristina, Vernero, Marta, Ribaldone, Davide Giuseppe, Alimenti, Eleonora, Manes, Gianpiero, Saibeni, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136459/
https://www.ncbi.nlm.nih.gov/pubmed/37190126
http://dx.doi.org/10.3390/cancers15082197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136459/
https://www.ncbi.nlm.nih.gov/pubmed/37190126
http://dx.doi.org/10.3390/cancers15082197

Ejemplares similares